Showing posts with label MRSA. Show all posts
Showing posts with label MRSA. Show all posts

Sunday, April 26, 2015

History repeating itself: using the medicine of the past to find the treatments of the future

With the vast number of medical studies that are reported every week, it can feel as though researchers are on a steady and direct march onward into the future, discovering new things about diseases and new forms of treatment day-by-day.

Medieval anatomy manuscript.
What lessons are left to learn from historical medical practices considering the progress that has been made by medicine over the past few decades?
Occasionally, though, a story will emerge where researchers revisit medicine that has long since been abandoned by the establishment and consigned to the murky depths of the past. When these stories occur, they often capture the imagination.
At the start of this month, Medical News Today reported on one such study, in which researchers from the University of Nottingham in the UK may have a discovered a potential new treatment for methicillin-resistant Staphylococcus aureus (MRSA) in an unlikely source: a 1,000-year-old medieval manuscript.
The eye infection remedy that the researchers found in Bald's Leechbook, a book containing a collection of Anglo-Saxon remedies for a variety of ailments, was as effective if not better at killing MRSA than conventional antibiotics.
As stated before, this kind of discovery is not an isolated incident. Over the past year, MNT have reported on a number of similar studies in which researchers have found inspiration for future treatments and approaches in the medicine of the past.
Why is it that history consistently offers the present and future new ideas for avenues of research, especially when our collective understanding of the human body and health has progressed so far over the past 1,000 years? In this Spotlight feature, we attempt to find out.

Ebola virus and historical precedence

The Ebola crisis that dominated world news last year produced two papers that looked to the past as a way of remedying the present.
When two American missionaries contracted the Ebola virus, an experimental drug untested on humans known as ZMapp was administered. Following this treatment, the missionaries made what was referred to as a miraculous recovery from the disease that has a case fatality rate of around 90%.
In the Annals of Internal Medicine, Dr. Scott Podolsky stated that development of the ZMapp treatment had much in common with methods of treating illness that were developed toward the end of the 19th century, inspired by the work of luminary microbiologists such as Louis Pasteur and Robert Koch.
ZMapp was created by collecting antibodies formed in the blood of mice after exposing them to fragments of the Ebola virus, mirroring the technique of passive serotherapy that was originally used to treat diseases such as pneumonia and meningitis.
One team of researchers chose to look even further back into history to find ways of dealing with the Ebola virus. Dr. Igor Linkov, a visiting professor of the Ca Foscari University, Italy, and colleagues believe that 14th century Venice holds many lessons on how to deal with such a crisis.
Person in hazardous materials outfit holding Ebola test tube.
Forms of infection control utilized in 14th century Venice could be used to inform management of the Ebola virus.
In 1347, the city became the epicenter of a plague epidemic. After initial attempts to fight the disease with prayer and ritual, the Venetians eventually responded by instigating what experts have termed "resilience management."
Although they did not understand the disease itself, the authorities introduced a system of inspection, quarantine stations on nearby islands and the wearing of protective clothing. These measures helped Venice to remain prosperous even after the initial devastation wrought by the plague.
"Resilience management can be a guide to dealing with the current Ebola outbreak in Africa, and others like it, as well as other issues like population growth and the impacts of global climate change," states Dr. Linkov.
"Similar to what the officials of Venice did centuries ago, approaching resilience at the system level provides a way to deal with the unknown and unquantifiable threats we are facing at an increasing frequency."
This example illustrates one simple reason researchers might be inclined to examine the past to treat diseases of the future: historical precedence. The parallels between the epidemics faced by 14th century Venice and present day West Africa are numerous enough to suggest that one or two lessons learned then may still be applicable. Here, history is repeating itself.

Lost knowledge

The example of the medieval eye remedy explains why discoveries can be made using historical sources many years after they were first recorded. In the case of Bald's Leechbook, the knowledge contained within was only made accessible after the manuscript was translated.
The recipe was chosen to be tested by the researchers because the recipe contained ingredients such as garlic that are currently being studied by others for their antibiotic potential.
"We believe modern research into disease can benefit from past responses and knowledge, which is largely contained in nonscientific writings," states study author Dr. Christina Lee. "But the potential of these texts to contribute to addressing the challenges cannot be understood without the combined expertise of both the arts and science."
Manuscripts such as Bald's Leechbook contain recipes that are designed to treat ailments that researchers can now identify as bacterial infections affecting areas of the body such as the eyes, skin, throat and lungs.
"Given that these remedies were developed well before the modern understanding of germ theory, this poses two questions," states Dr. Lee. "How systematic was the development of these remedies? And how effective were these remedies against the likely causative species of bacteria?"
As well as satisfying a particular curiosity by exploring how people in Medieval times approached medicine, the team from the University of Nottingham describe another factor that drives this form of research.
"There is a pressing need to develop new strategies against pathogens because the cost of developing new antibiotics is high and eventual resistance is likely," explains study leader Dr. Freya Harrison, from the School of Life Sciences.
"This truly cross-disciplinary project explores a new approach to modern health care problems by testing whether medieval remedies contain ingredients which kill bacteria or interfere with their ability to cause infection."
Forms of medicine used in the past may have successfully treated certain forms of disease, even if those who administered these treatments were unaware how they worked - much like the authorities of 14th century Venice implementing resilience management. Today, researchers can analyze treatments that were used with success hundreds of years ago and explore the mechanisms behind them.

Re-evaluating traditional medicine

This appraisal of historical medicine is not limited to forms of treatment that may have been previously lost to the past. Researchers are regularly assessing traditional medicine or individual components of folk remedies used for hundreds of years within specific cultures.
A paper published in EMBO Reports examines whether ancient medical knowledge can lead researchers to new drug combinations. "Since our earliest ancestors chewed on certain herbs to relieve pain, or wrapped leaves around wounds to improve healing, natural products have often been the sole means to treat diseases and injuries," the authors explain.
In recent decades, natural products have taken a secondary role in drug discovery and development, but the authors of the paper suggest that over the last few years, attitudes toward natural products have changed:
"The modern tools of chemistry and biology - in particular, the various '-omics' technologies - now allow scientists to detail the exact nature of the biological effects of natural compounds on the human body, as well as to uncover possible synergies, which holds much promise for the development of new therapies against many devastating diseases, including dementia and cancer."
MNT have reported on a number of examples of this form of research over the past year.
Roseroot is a herb that has been used in traditional European folk medicine for over 3,000 years. A recently conducted study has suggested it could be a potential treatment option for depression by stimulating the receptors of neurotransmitters in the brain that are associated with mood regulation.
The herb has been used in traditional medicine to promote work endurance, increase longevity and promote resistance to a number of health conditions including fatigue and depression.
In a previous Spotlight feature, MNT examined the history of fecal microbiota transplants. Although this form of therapy is slowly growing more prominent, the practice of using human stool to treat illness can be traced all the way back to 4th century China.
Literature of this era - perhaps similar to Bald's Leechbook - makes reference to stool being used to treat food poisoning and diarrhea. Evidence of the practice exists throughout history up until World War II, when German soldiers stationed in Africa observed that a Bedouin remedy involving the consumption of camel dung was effective in treating bacterial dysentery.
Also found in traditional Chinese medicine is honeysuckle, frequently consumed in the form of tea. Last year, researchers identified a molecule within the plant that directly targets a family of viruses that includes Spanish flu and avian flu.
By discovering what elements of traditional medicine have curative properties, researchers can develop new forms of treatment that may be effective where the efficacy of current forms of treatment is slowly lessening.

Old solutions for new problems

Many health professionals are concerned that we are approaching - or indeed have reached - a postantibiotic era. Antimicrobial resistance is an urgent issue that many researchers are spending considerable amounts of time and energy into addressing.
Ancient books and laptop.
Present day research into disease can benefit from the insight of the past.
More and more microbial pathogens are adapting and evolving in ways that render them resistant to the antimicrobial drugs that had redefined health care in the 20th century.
"Antibiotics transformed the very practice of medicine," explains Dr. Podolsky. "By the late 1980s and early 1990s, however, in the wake of the AIDS epidemic, increasingly identified antibiotic resistance, public health retrenchment, and increasing globalization, such initial optimism had given way to fears regarding 'emerging infections' and a 'world out of balance.'"
A time is approaching where the solutions that have been so effective for so long are no longer able to protect people from disease. As this time draws nearer, scientists need to be developing new strategies of dealing with illness.
In the pre-antibiotic era, such strategies were used out of necessity. It is not surprising that, as a result, many researchers are looking to the past and revisiting previously used methods with a fresh eye in order to create new forms of treatment.
Yes, there is evidence of history consistently repeating itself, but it is equally true that new challenges will also present themselves. By combining hindsight and new breakthroughs in scientific knowledge, researchers may already have the materials to solve these challenges at their disposal.
It could simply be a matter of looking in the right place, or time.
Continue to Read more ...

Tuesday, April 14, 2015

CDC: drug-resistant intestinal bug spreading in US

A group of bacteria called Shigella is responsible for 500,000 cases of diarrhea in the US every year. Now a new report says a multi-drug resistant strain of the bug is entering the country in infected travelers and causing a series of outbreaks.

washing hands
The CDC recommend people wash their hands often with soap and water to prevent spread of the diarrhea illness shigellosis.
Shigella causes shigellosis - an intestinal illness that is accompanied by watery or bloody diarrhea, abdominal pain, fever and malaise.
The Centers for Disease Control and Prevention (CDC) say a strain of Shigella sonnei - the most common species of Shigella in the US - that is resistant to the antibiotic ciprofloxacin (Cipro) infected 243 people in 32 states and Puerto Rico between May 2014 and February 2015.
Shigella is one of the types of bacteria that cause intestinal illness in travelers going from developed countries to under-developed countries. This "traveler's diarrhea," is variously referred to as "Montezuma's revenge," or "Delhi belly," or the "Turkey trots."
The bacteria are found in water used for drinking, to wash food or to irrigate crops, that has been contaminated by human or animal stools.
Cipro is a first choice drug for treating shigellosis among adults in the US. Until recently, Cipro resistance was only found in around 2% of Shigella infections tested in the US.
In the new report - which describes investigations into recent clusters of Shigella infection in Massachusetts, California and Pennsylvania - the CDC say Cipro resistance was found in 90% of the samples tested.
Some people infected with Shigella only have mild symptoms, but this does not stop the bug from spreading. The report says that in these outbreaks, the bacteria spread easily in childcare facilities and among homeless people and gay and bisexual men.

Investigators found unique strain of Cipro-resistant Shigella

CDC Director Dr. Tom Frieden says the outbreaks they investigated are a troubling trend:
"Drug-resistant infections are harder to treat and because Shigella spreads so easily between people, the potential for more - and larger - outbreaks is a real concern."
Dr. Frieden states the US is moving quickly to put in place a national plan to curb antibiotic resistance, because "we can't take for granted that we'll always have the drugs we need to fight common infections."
In the US, most strains of Shigella are already resistant to the antibiotics ampicillin and trimethoprim/sulfamethoxazole. Around the world, Shigella is becoming more resistant to Cipro, which is often prescribed to people traveling out of the US in case they develop diarrhea while abroad.
The report describes how through the CDC's PulseNet lab network, it was possible to identify an increase in shigellosis cases caused by a unique strain of Cipro-resistant Shigella. About half of the cases were people known to have returned from the Dominican Republic, India and other places outside the US.
The CDC recommend good hygiene habits to prevent the spread of Shigella, including:
  • Wash hands frequently with soap and water
  • Always wash hands with soap and water after using the toilet, and before preparing food and eating
  • If your child is sick with diarrhea, keep them home and away from childcare and group activities
  • Don't prepare food for others if you have diarrhea
  • Avoid swimming pools and other public water places for a few weeks as you recover from a diarrhea illness.
Dr. Anna Bowen, a medical officer in CDC's Waterborne Diseases Prevention Branch, and lead author of the report, says:
"Washing your hands with soap and water is important for everyone. Also, international travelers can protect themselves by choosing hot foods and drinking only from sealed containers."
Scientists are starting to discover that antibiotic use - and overuse especially - is linked to a range of problems that affect, among other things, the immune system, glucose metabolism, food digestion, gut health and behavior.
For instance, in February 2015, Medical News Today reported another study that showed antibiotic use has more more unwanted side effects on the gut than previously thought. In that study, led by the College of Pharmacy at Oregon State University, Corville, researchers tested the effect of four antibiotics commonly given to lab animals.
Previously, it was thought the drugs only killed bacteria and blocked some immune functions in the gut. However, the study found they also destroy cells in the lining of the gut.
Continue to Read more ...

Saturday, April 4, 2015

1,000-year-old potion shows promise against MRSA

MRSA has become one of the deadliest bacteria of modern times. The cause of more than 80,000 severe infections in the US every year, the "superbug" has evolved to develop resistance to many antibiotics that once killed it. But researchers from the University of Nottingham in the UK say they may have uncovered a new treatment for MRSA: a 1,000-year-old remedy for eye infections taken from a manuscript found in the British Library.

MRSA
The ancient potion - made of garlic, onion or leek, wine and cow bile - proved effective against the superbug MRSA.
Dr. Christina Lee, associate professor in Viking studies and a member of the Institute for Medieval Research at the University of Nottingham, and colleagues say the remedy killed up to 90% of MRSA (methicillin-resistantStaphylococcus aureus) in vivo.
What is more, studies in mouse models of MRSA conducted by researchers from Texas Tech University in Lubbock found the ancient potion presented "astonishing" results against the superbug.
The researchers are due to present their findings at the Annual Conference of the Society for General Microbiology in Birmingham, UK.
MRSA is a type of Staphylococcus, or "staph," bacteria that can be spread through skin-to-skin contact. It can cause skin infections and - particularly in health care settings - bloodstream infections, pneumonia and surgical site infections.
The Centers for Disease Control and Prevention (CDC) estimate that in 2011, MRSA was the cause of 80,461 invasive infections and was related to 11,285 deaths in the US. Most MRSA infections occur in health care settings.
MRSA infections are becoming harder to treat. Many antibiotics that were once effective against the bacteria - including methicillin, oxacillin and nafcillin - no longer work. As a result, researchers across the globe are trying to find new ways to kill the superbug.
Now, Dr. Lee and colleagues believe a 10th century Old English manuscript may hold a remedy for MRSA infections.

Ancient potion requires cow bile, garlic, onion and wine

The manuscript was found in Bald's Leechbook, which is believed to be one of the earliest ever medical textbooks. The book contains an array of Anglo-Saxon remedies for a number infections, and a potion for an eye infection caught Dr. Lee's attention.
"Medieval leech books and herbaria contain many remedies designed to treat what are clearly bacterial infections," says Dr. Lee. "Given that these remedies were developed well before the modern understanding of germ theory, this poses two questions: How systematic was the development of these remedies? And how effective were these remedies against the likely causative species of bacteria?"
"Answering these questions will greatly improve our understanding of medieval scholarship and medical empiricism," she continues, "and may reveal new ways of treating serious bacterial infections that continue to cause illness and death."
Dr. Lee translated the recipe for the ancient eye infection potion. The recipe requires garlic, onion or leek, wine and bile from a cow's stomach, called oxgall. The potion must be brewed in a brass vessel, strained for purification and left for 9 days before being applied to the infected site.
Following the recipe's strict instructions, Dr. Lee and her colleagues made four batches of the potion using fresh ingredients for each batch.

Researchers 'blown away' by the potion's effectiveness against S. aureus

The team created artificial wounds infected with S. aureus by growing the bacteria in collagen. They then exposed the wounds to each potion ingredient individually or the full potion.
Applying each separate potion ingredient to the wounds appeared to have no effect against S. aureus. When the full potion was applied, however, they found it killed almost all of the bacteria, with only around one bacterial cell in every 1,000 surviving.
Next, the researchers diluted the potion and applied it to the infected wounds to determine how much of it would be needed to treat a real infection.
They found that diluting the potion to the extent that it is unable to kill S. aureus interrupts communication between bacterial cells. Dr. Lee and colleagues say this is an important discovery because bacterial cells have to communicate with each other in order to cause tissue damage, and many scientists believe halting such behavior could treat infection.
Study leader Dr. Freya Harrison, also of the University of Nottingham, says the team was surprised by the findings:
"We thought that Bald's eyesalve might show a small amount of antibiotic activity, because each of the ingredients has been shown by other researchers to have some effect on bacteria in the lab - copper and bile salts can kill bacteria, and the garlic family of plants make chemicals that interfere with the bacteria's ability to damage infected tissues. But we were absolutely blown away by just how effective the combination of ingredients was."
Dr. Harrison says the potion even proved effective in harsher conditions, killing S. aureus in "biofilms" created from extended growth of artificial infections. Biofilms occur when each bacterial cell clumps together, creating a sticky coating that can stop antibiotics from reaching them.
"When we found that [the potion] could actually disrupt and kill cells in S. aureus biofilms, I was genuinely amazed," says study co-author Dr. Steve Diggle.
"Biofilms are naturally antibiotic resistant and difficult to treat so this was a great result. The fact that it works on an organism that it was apparently designed to treat [an infection of a stye in the eye] suggests that people were doing carefully planned experiments long before the scientific method was developed."
The researchers explain their findings further in the video below:

Effectiveness of ancient remedy on par with previously used antibiotics

The ancient potion was also tested on mice with MRSA-infected skin wounds by Dr. Kendra Rumbaugh from Texas Tech University, and she found it was highly effective against the superbug.
"We know that MRSA infected wounds are exceptionally difficult to treat in people and in mouse models," says Dr. Rumbaugh. "We have not tested a single antibiotic or experimental therapeutic that is completely effective; however, this 'ancient remedy' performed as good if not better than the conventional antibiotics we used."
The researchers are now looking for further funding to test the effectiveness of this potion and other ancient remedies that may be effective against modern-day bacterial infections.
Dr. Harrison says further research into alternative treatments for such infections is crucial if we are to tackle the increasing problem of antibiotic resistance.
"There is a pressing need to develop new strategies against pathogens because the cost of developing new antibiotics is high and eventual resistance is likely," she explains. "This truly cross-disciplinary project explores a new approach to modern health care problems by testing whether medieval remedies contain ingredients which kill bacteria or interfere with their ability to cause infection."
Medical News Today recently reported on a study published in the Proceedings of the National Academy of Sciences, in which researchers claim an increase in the use of antibiotics in livestock over the next 15 years may fuel drug resistance.
Continue to Read more ...

Thursday, May 16, 2013

More Effective Treatment Of Complex Infections Likely With Cutting-Edge Bacteria Research

Bacteria are life forms, which, like all other life forms, struggle for the best living conditions for themselves. Therefore they will try to avoid getting attacked by the human immune system, and therefore they have developed various ways to protect themselves from the human immune system. When safe from the immune system, they can focus on breeding and multiplying, and if they become numerous enough, the human body will experience their presence as an infection. Some bacteria are relatively harmless, while others are fatal. The bacteria avoid being attacked by the human immune system by forming a biofilm - a surface to protect them against the immune system.

"The biofilm contributes to bacterial resistance, and that can cause severe, persistent infections around heart valve implants and in lungs and the urinary tract," explains postdoc. Mikkel Girke Jørgensen from the Department of Biochemistry and Molecular Biology at the University of Southern Denmark. Together with professor Poul Valentin-Hansen from the same institution and scientists from American Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, and Georgetown University Medical Center, Washington DC, he stands behind the new discovery.

The researchers now understand the underlying regulatory mechanisms behind the formation of biofilms. The mechanism involves small RNA molecules, which can affect bacterial gene expression and thus the decision of whether to form biofilm or not.

Bacteria can move by using their so-called flagella to swim with. When they need to form biofilms, they "turn off" the flagella, stop moving and start to form a biofilm.

"We have now established what decides whether they swim or not - and that determines whether they form biofilms or not," explains Mikkel Girke Jørgensen and continues:

"Prospects for the pharmaceutical industry are huge. This increased understanding of biofilm formation may be the first step in creating new ways to treat complicated infections in the future. "
Continue to Read more ...

Friday, March 15, 2013

Antibiotic No Better For Coughs, Uncomplicated Chest Infections Than No Medication

Amoxicillin, the antibiotic doctors often prescribe for persistent coughs caused by uncomplicated chest infections such as bronchitis, is no more effective at easing symptoms than no medication at all, even in older patients. This was the finding of the largest randomised placebo controlled trial of antibiotics for lower respiratory tract infections (LRTI) done to date.

The study, which was led by the University of Southampton in the UK, is from the GRACE (Genomics to Combat Resistance against Antibiotics in Community-acquired LRTI in Europe) consortium and was funded by the European Community's Sixth Framework Programme.

A paper on the findings appears in the 19 December online issue of The Lancet Infectious Diseases.

First author Paul Little, Professor of Primary Care Research at Southampton, says in a statement:

"Patients given amoxicillin don't recover much quicker or have significantly fewer symptoms."

In fact, he adds, using amoxicillin to treat patients with respiratory infections who don't have pneumonia could not only be ineffective, but might actually harm them.

"Overuse of antibiotics, which is dominated by primary care prescribing, particularly when they are ineffective, can lead to side effects such as diarrhea, rash, vomiting and the development of resistance," he explains.

The European Centre for Disease Prevention and Control (ECDC) recently put out a statement saying that antibiotic resistance remains a major threat to public health around the world, and for the large part, the cause is misuse of antibiotics.

Chest infections, also known as lower respiratory tract infections (LRTI), are one of the most common acute illnesses treated in primary care settings in developed countries.

There is a lot of controversy about whether LRTI, especially in older people, should be treated with antibiotics, especially since viruses are thought to cause most of them, and previous studies have shown inconsistent results.

A recent study presented at CHEST 2012, the annual meeting of the American College of Chest Physicians, also suggests antibiotics are not successful in treating cough due to the common cold in children.

For this latest GRACE study, the researchers recruited 2,061 adults attending primary care practices with straightforward mild chest infections. The practices were located in 12 European countries: England, Wales, Netherlands, Belgium, Germany, Sweden, France, Italy, Spain, Poland, Slovenia, and Slovakia.

The participants were randomly assigned to be prescribed either amoxicillin or a placebo, to be taken three times a day for seven days.

The prescribing general practitioners (GPs) assessed their patients' symptoms at the start of the study period, and the patients also filled in diaries of their daily symptoms.

When they analyzed this data, the researchers found there was little difference in how severe the symptoms were or how long they lasted for, between the amoxicillin and placebo groups.

Even in those aged 60 and over with no other illnesses, antibiotics seemed to offer little benefit over placebo.

Patients in the antibiotic group reported significantly more side effects, including rash, nausea and diarrhea.

The researchers did conclude, however, that while most people seem to get better on their own, there is a small number of patients who do benefit from antibiotics, and "the challenge remains to identify these individuals," says Little.

In an accompanying commentary, Philipp Schuetz, from the University of Basel in Switzerland, notes:

"Little and colleagues have generated convincing data that should encourage physicians in primary care to refrain from antibiotic treatment in low-risk patients in whom pneumonia is not suspected."

However, the question remains, he says, of whether this "one-size-fits-all approach can be further improved".

He suggests perhaps one way to avoid the "toxic effects and costs" of antibiotics and "the development of resistance in the other patients", is to test for "specific blood biomarkers of bacterial infection", so as to "identify the few individuals who will benefit from antibiotics despite the apparent absence of pneumonia".
Continue to Read more ...

Tuesday, December 25, 2012

Antibiotic No Better For Coughs, Uncomplicated Chest Infections Than No Medication

Amoxicillin, the antibiotic doctors often prescribe for persistent coughs caused by uncomplicated chest infections such as bronchitis, is no more effective at easing symptoms than no medication at all, even in older patients. This was the finding of the largest randomised placebo controlled trial of antibiotics for lower respiratory tract infections (LRTI) done to date.

The study, which was led by the University of Southampton in the UK, is from the GRACE (Genomics to Combat Resistance against Antibiotics in Community-acquired LRTI in Europe) consortium and was funded by the European Community's Sixth Framework Programme.

A paper on the findings appears in the 19 December online issue of The Lancet Infectious Diseases.

First author Paul Little, Professor of Primary Care Research at Southampton, says in a statement:

"Patients given amoxicillin don't recover much quicker or have significantly fewer symptoms."

In fact, he adds, using amoxicillin to treat patients with respiratory infections who don't have pneumonia could not only be ineffective, but might actually harm them.

"Overuse of antibiotics, which is dominated by primary care prescribing, particularly when they are ineffective, can lead to side effects such as diarrhea, rash, vomiting and the development of resistance," he explains.

The European Centre for Disease Prevention and Control (ECDC) recently put out a statement saying that antibiotic resistance remains a major threat to public health around the world, and for the large part, the cause is misuse of antibiotics.

Chest infections, also known as lower respiratory tract infections (LRTI), are one of the most common acute illnesses treated in primary care settings in developed countries.

There is a lot of controversy about whether LRTI, especially in older people, should be treated with antibiotics, especially since viruses are thought to cause most of them, and previous studies have shown inconsistent results.

A recent study presented at CHEST 2012, the annual meeting of the American College of Chest Physicians, also suggests antibiotics are not successful in treating cough due to the common cold in children.

For this latest GRACE study, the researchers recruited 2,061 adults attending primary care practices with straightforward mild chest infections. The practices were located in 12 European countries: England, Wales, Netherlands, Belgium, Germany, Sweden, France, Italy, Spain, Poland, Slovenia, and Slovakia.

The participants were randomly assigned to be prescribed either amoxicillin or a placebo, to be taken three times a day for seven days.

The prescribing general practitioners (GPs) assessed their patients' symptoms at the start of the study period, and the patients also filled in diaries of their daily symptoms.

When they analyzed this data, the researchers found there was little difference in how severe the symptoms were or how long they lasted for, between the amoxicillin and placebo groups.

Even in those aged 60 and over with no other illnesses, antibiotics seemed to offer little benefit over placebo.

Patients in the antibiotic group reported significantly more side effects, including rash, nausea and diarrhea.

The researchers did conclude, however, that while most people seem to get better on their own, there is a small number of patients who do benefit from antibiotics, and "the challenge remains to identify these individuals," says Little.

In an accompanying commentary, Philipp Schuetz, from the University of Basel in Switzerland, notes:

"Little and colleagues have generated convincing data that should encourage physicians in primary care to refrain from antibiotic treatment in low-risk patients in whom pneumonia is not suspected."

However, the question remains, he says, of whether this "one-size-fits-all approach can be further improved".

He suggests perhaps one way to avoid the "toxic effects and costs" of antibiotics and "the development of resistance in the other patients", is to test for "specific blood biomarkers of bacterial infection", so as to "identify the few individuals who will benefit from antibiotics despite the apparent absence of pneumonia".

Written by Catharine Paddock PhD
Continue to Read more ...

Monday, August 6, 2012

Super Antibiotic For Hospital Superbug MRSA

Merck scientists have discovered an antibiotic that is effective in destroying MRSA, otherwise known as the hospital superbug. This antibiotic, unlike others, blocks the enzymes that produce fatty acids - essential for the construction of the membranes of bacteria. The compound binds to FabF.

If the drug successfully passes clinical trials, it will be only the third new antibiotic type in the last four decades. Most modern antibiotics still work on variations of compounds discovered in the late 1940s to 1950s. Current antibiotics either inhibit a bacterium's ability to build a membrane or prevent it from creating proteins or DNA.

This fact, that most antibiotics are basically quite similar, may be one of the main reasons for the increasing incidence of antibiotic resistance. Antibiotic resistance is also the result of overuse of antibiotics.

Any completely new type of antibiotic is viewed with enthusiasm by doctors because it may smash resistance on the head and give us a headstart of many decades.

The researchers were looking through more than one quarter of a million natural products when they came across 'platensimycin' found in a soil sample from South Africa. Platensimycin is produced by Streptomyces platensis, an actinomycete bacteria. Platensimycin was found to be a powerful inhibitor of many Gram-positive bacteria, including many Staphylococcus strains.

Initially, researchers found that platensimycin eliminated S. aureus bacteria, related to MRSA, from infected mice. According to their preliminary investigations, there were no toxic side-effects. After further tests, they found platensimycin to be very effective against MRSA and many other types of bacteria.

This could be welcome news for doctors who are concerned at the rising numbers MRSA infection cases in hospitals throughout most of the world. The majority of pharmaceutical companies have moved away from antibiotic research. Over the last ten years the number of new antibiotics coming onto the market has gone down, while the number of MRSA cases has been steadily rising. MRSA is resistant to most antibiotics.

The scientists said that this potential breakthrough is in its birth and we could be looking at several years before a new, effective and safe product is on the market.
Continue to Read more ...
Related Posts Plugin for WordPress, Blogger...

Popular Posts